RxDoctor Payments Data

Ratan Tiwari, MD

Interventional Cardiology · Hemet, CANPI 1396775847

Payments from drug & device makers

$7,660in general payments, 2019–2025

Across 435 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Terumo Medical Corporation$1K
  • Novartis$604
  • Johnson & Johnson$544
  • Boehringer Ingelheim$427
  • Abbott$399
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$1,19316%
  • Food & beverage$6,34983%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,660 in reported general payments places this provider in the 40th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$162,788
Medicare patients
315
Services billed
1,824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$202,494
EntrestoSacubitril/Valsartan71$79,033
XareltoRivaroxaban35$37,347
JardianceEmpagliflozin11$11,804
Ranolazine ErRanolazine142$9,701
Metoprolol Succinate356$4,736
Diltiazem Hcl67$2,101
Amiodarone Hcl37$1,903
Nitroglycerin142$1,831
Atorvastatin Calcium126$1,753
Rosuvastatin Calcium104$1,607
Midodrine Hcl24$1,579
Carvedilol208$1,508
Digoxin71$1,405
Losartan Potassium148$1,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$202,494215 claims
NovartisEntresto$604$79,03371 claims
Johnson & JohnsonXarelto$544$37,34735 claims
Boehringer IngelheimJardiance$427$11,80411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →